Printer Friendly

LECTEC SMOKING CESSATION PATCH DEVELOPMENT PROGRESSES; PATENT PENDING

LECTEC SMOKING CESSATION PATCH DEVELOPMENT PROGRESSES; PATENT PENDING
 MINNETONKA, Minn., May 26 /PRNewswire/ -- LecTec Corporation (NASDAQ: LECT) today released further details concerning its smoking cessation product development project. An announcement, dated Jan. 7, 1992, was made concerning the agreement between LecTec and the University of Minnesota to develop nicotine-free smoking cessation transdermal and oral dosage products. The potential market in the United States for smoking cessation products is projected to exceed $1 billion. There are an estimated 50 million smokers in the United States.
 All current smoking cessation prescription products contain nicotine as the active ingredient. Research of the nicotine-free active ingredient in development indicates that the future product will be less toxic and, likely, safer to use than existing products.
 Human and animal studies have demonstrated the non-addictive properties of the nicotine-free active. Among the limitations of nicotine-containing smoking cessation products is the potential for addiction to the active ingredient. LecTec researchers believe that their work will result in a safer product as a result of the elimination of the addiction potential. A patent has been filed and is pending for the nicotine-free technology in development.
 According to Dr. Thomas E. Brunelle, senior vice president of LecTec, "We are very encouraged by the initial results and progress of this project. A number of well-known pharmaceutical companies have contacted us. We are in preliminary discussion with one of these prominent companies to explore a potential strategic alliance and assure expeditious movement of this future product into the world marketplace."
 LecTec Corporation is a manufacturer and marketer of various medical electrodes, conductive adhesive membranes, tapes and transdermal drug delivery systems. The company is traded on NASDAQ under the symbol LECT.
 -0- 5/26/92
 /CONTACT: Jan Jachimowicz of LecTec, 612-933-2291/
 (LECT) CO: LecTec Corporation ST: Minnesota IN: MTC SU: PDT


KH -- MN004 -- 3751 05/26/92 12:10 EDT
COPYRIGHT 1992 PR Newswire Association LLC
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 1992 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:PR Newswire
Date:May 26, 1992
Words:308
Previous Article:APACHE TO REDEEM CONVERTIBLE DEBENTURES
Next Article:TOYOTA SALES RISE IN SECOND 10-DAY PERIOD OF MAY
Topics:


Related Articles
UNIVERSITY OF MINNESOTA, LECTEC AGREE TO DEVELOP NICOTINE-FREE SMOKING CESSATION TREATMENT
MOST NICOTINE PATCH USERS DOOMED TO FAIL
CYGNUS SHIPS ITS NICOTINE PATCH
LECTEC RESPONDS TO FDA ADVISORY PANEL INVESTIGATING REPORTS OF ADVERSE REACTIONS OF NICOTINE PATCHES
LEDERLE REBATING ONE-THIRD THE COST OF PROSTEP(R) NICOTINE PATCH THERAPY, AND DONATING 1 MILLION MORE PATCHES TO ASTHO
LEDERLE EXTENDS PROSTEP REBATE THROUGH END OF YEAR TO MAKE PRESCRIPTION NICOTINE PATCH MORE ACCESSIBLE IN LIGHT OF FDA BAN ON OVER-THE-COUNTER...
Sano Corporation Reports Positive Results From Phase II Trial Of New Therapeutic For Smoking Cessation
The LifeSign(R) Stop Smoking Computer: Still the Only Drug-Free, Scientifically Proven Program Today
The LifeSign(R) Stop Smoking Computer: Still the Only Drug-Free, Scientifically Proven Program Today
A patch of all trades: transdermal systems use nonwovens to ease pain or offer relief.

Terms of use | Copyright © 2016 Farlex, Inc. | Feedback | For webmasters